Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study
DOYLESTOWN, Pa., July 22 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY ) www.quigleyco.com , today announced the results from its Phase IIb
double-blind, placebo-controlled, study of topical compound QR-333 for the tre...
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX ) today announced that results from the week-60 analysis for its Phase IIb
dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis...
Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
DOYLESTOWN, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Quigley Pharma Inc.,
a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY )
announced today that the last subject in the Phase IIb
Study is scheduled
to complete treatment on November 25, 2008. This will effectively move the
Merck's odanacatib increased BMD over 2 years at key fracture sites in Phase IIB study
WHITEHOUSE STATION, N.J., Sept. 16, 2008 Two-year data from a Phase IIB
study of odanacatib (formerly MK-0822), an investigational, selective cathepsin-K inhibitor in development for the treatment of osteoporosis by Merck & Co., Inc., demonstrated dose- dependent increases in bone mineral density...
Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
Top-line data expected in early 2008
TARRYTOWN, N.Y., Dec. 3 /PRNewswire-FirstCall/ -- EpiCept Corporation
(Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has
completed patient enrollment in the Phase IIb
"Neuracept" trial for
EpiCept(TM) NP-1 cream. EpiCept NP...
AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL
MONTREAL, Sept. 5 /PRNewswire-FirstCall/ - AKELA Pharma Inc., (TSX:
AKL), a drug development company focused on developing therapies for the
inhalation, pain and CNS markets, today announced positive results from the
DURECT Corporation Announces Second Quarter 2009 Financial
... enrollment in our approximately 60 patient Phase iib
clinical study in
shoulder surgery. In add...on, Nycomed continued enrollment in a
study in hysterectomy patients and a Phase iib
shoulder surgery patients. We are...
Glenmark Brings to the Notice of the Authorities Irregularities of the Clinical Investigator at its Jamnagar Site in Gujarat
...er General of India(DCGI)
for a multi-centre Phase iib
clinical study for its lead COPD/asthma
molecule, ...ions were completed prior to initiating this phase iib
Being a multi-centre clinical study,... from this site pertaining to the study. The Phase iib
continues to progress as per plan at other s...
Mount Sinai researchers find new Alzheimer's disease treatment promising
...Alzheimer's Disease (ICAD) in Vienna on Sunday, July 12.
NIC5-15's potential to preserve cognitive performance will be further evaluated in a Phase iib
clinical trial. Early evidence suggests that NIC5-15 is a safe and tolerable natural compound that may reduce the progression of Alzheimer's disease-r...
NEJM study points to new era in hepatitis C treatment
...ndard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.
Results of the Phase iib
clinical trial -- led by Duke Clinical Research Institute (DCRI) and 36 other sites, including NewYork-Presbyterian Hospital/Weill Cornell Medical Cen...
IIB in Medical Technology
Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Start of trial triggers $10 million milestone payment to Pharmasset
PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today announced that the first patient has been dosed in a Phase IIb
study of R7128, th...
DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
CUPERTINO, Calif., March 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX ) announced today positive results from a 74 patient Phase IIb
clinical trial conducted by Endo Pharmaceuticals of TRANSDUR(TM)-Sufentanil, a proprietary seven day patch under development for the treatment of ...
Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma
BERKELEY, Calif., March 2 /PRNewswire/ -- Aerovance Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb
clinical trial, AeroTrial(TM), of inhal...
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
IRVINE, Calif., Jan. 22 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced positive results from the Company's Phase IIb
clinical study of ecabet sodium, which is being developed as a treatment for dry eye disease. Patients treated with ecabet sodium achieved ...
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
WILMINGTON, Del. and WINSTON-SALEM, N.C., Dec. 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) and Targacept, Inc. today announced top-line results from a Phase IIb
clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HAL...
Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
- Milestone Marks the First Time a European Patient with Active Celiac
Disease has Enrolled in a Clinical Trial for an Investigational Medication from Alba Therapeutics -
BALTIMORE, Nov. 11 /PRNewswire/ -- Alba Therapeutics Corporation
announced today that for the firs...
BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronie's Disease
LYNBROOK, N.Y. Sept. 17 /PRNewswire-FirstCall/ -- BioSpecifics
Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company
developing first in class collagenase based products, announced today the
initiation of a U.S. Phase IIb
clinical trial in Peyronie's disease for its
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease
WILMINGTON, Del., Sept. 15 /PRNewswire-FirstCall/ --
-- Results inconclusive, as primary outcome measure not statistically significant for either donepezil or AZD3480; results impacted by improvement in placebo group
-- Improvements shown on secondary outcome measures ADCS-CGIC an...
Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
- Approval of Second IND Marks Major Corporate Milestone and Advances Clinical Program -
ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals,
Inc. today announced the approval of its second investigational new drug
(IND) application for a Phase IIb
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
Orexigen is the only company with two late-stage product candidates to address a broad spectrum of obesity patients
SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics,
Inc. (Nasdaq: OREX ) announced today that it has begun randomizing patients
in ZB-202, a seco...
IIB in Biological News
Anabolic steroids provide a competitive edge in power lifting years after doping has ended
...ce. Type IIA is the strongest and fastest, but has the least endurance. Human muscles occur along a continuum of fiber types. For power lifters, type iib
fiber, the most powerful, is most frequently used. The use of anabolic steroids can add more nuclei to the muscle, and enhance muscle fiber size.
30+ AIDS vaccine clinical trials in 24 countries, research occurring on every continent
...om Sanofi-Pasteur and Merck & Co., Inc. Data from Merck's ongoing Phase iib
test-of-concept trial with its adeno-5 vector vaccine candidate is expected...lopment efforts. The company will also soon be starting an additional Phase iib
trial with the same candidate in South Africa.
The Joint United N...
'Marathon mice' elucidate little-known muscle type
...ontent, the researchers now report. Upon further examination, the researchers were surprised to find that the fibers showed a reduction in I, IIA, and iib
MHCs and as much as a 5-fold increase in IIX MHC.
Nearly 100% of muscle fibers in the transgenic animals contained abundant MHC IIX mRNA and pro...
Africa's first large-scale HIV vaccine study launches
...ilar between different strains of HIV-1."
The study is known as a phase iib
or "test of concept" efficacy trial because it enables researchers to deter...ect against the clade C virus, the subtype prevalent in South Africa. Phase iib
trials cannot be used to support licensure of a vaccine, however, the data ...
IIB in Biological Technology
Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
ALISO VIEJO, Calif., June 1 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX ) today reported final results for its Phase IIb
dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C i...
Advanced Viral Announces Phase IIb Wound Healing Trial for AVR123
Receives $249,500 in Additional Financing
YONKERS, N.Y., Oct. 28 /PRNewswire-FirstCall/ -- Advanced Viral
Research Corp. (OTC Bulletin Board: ADVR), announced today that it has
commenced a Phase IIb
efficacy study for AVR123 in wound healing.
The Phase IIb
trial is being conducted at the F...
Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
ROCKVILLE, Md., Oct. 20 /PRNewswire/ -- Glycotex, Inc. today announced
enrollment of the first patient in a Phase IIb
study evaluating the effect
of GLYC-101 on wound closure and cosmetic outcomes in cosmetic surgery
patients undergoing carbon dioxide laser skin resurfacing on the lower
TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
LA JOLLA, Calif., June 23 /PRNewswire/ -- TorreyPines Therapeutics,
Inc. (Nasdaq: TPTX ) today announced that Dr. Neil Kurtz, President and
Chief Executive Officer, will present data obtained from the Phase IIb
study that evaluated the safety, tolerability and efficacy of three doses
Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
BALTIMORE, May 16 /PRNewswire/ -- Alba Therapeutics Corporation
announced today that it has enrolled and randomized its first patient in a
twelve-week Phase IIb
trial with oral larazotide acetate, an inhibitor of
intestinal barrier dysfunction, for the treatment of patients with active
Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
STRASBOURG, France, January 10 /PRNewswire-FirstCall/ -- Transgene
(Euronext Paris: FR0005175080) announces promising preliminary data from
the Phase IIb
trial evaluating its therapeutic vaccine TG4010
(MVA-MUC1-IL2) as an adjunct to first line chemotherapy in patients with
advanced non-small ...
Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
LONDON, November 26 /PRNewswire/ -- Daval International Limited, a UK
private company, announces MHRA and IRB (Ethics Committee) approval of a
London based Phase IIB
trial of AIMSPRO(R), its hyperimmune caprine serum
This double-blind placebo-controlled cross-over study will seek...
Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
DOYLESTOWN, Pa., Sept. 11 /PRNewswire-FirstCall/ -- The Quigley
Corporation (Nasdaq: QGLY ) today issued an update on a Phase IIb
Study of QR-333 on Diabetic Peripheral Neuropathy by its wholly owned
subsidiary, Quigley Pharma, http://www.QuigleyPharma.com . The update on the study...
Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
VALLEY COTTAGE, New York, September 11 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE: XTL; TASE: XTL) will hold a
conference call today, September 11, 2007, at 8:30 a.m. EDT to discuss the
clinical trial of Bicifadine for the treatment of diabetic
XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
Company to Hold a Conference Call Tomorrow (Tuesday) at 8:30 am EDT to Discuss the Clinical Trial
Valley Cottage, NEW YORK, September 10 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE: XTL; TASE: XTL) today announced
the initiation of a Phase ...
IIB in Biological Products